Headlines about Alkermes (NASDAQ:ALKS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alkermes earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.6757326489474 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
- Alkermes’ Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference (finance.yahoo.com)
- Alkermes – 2018 Shaping Into Excellent Year (seekingalpha.com)
- Alkermes Plc (ALKS) Expected to Announce Quarterly Sales of $254.43 Million (americanbankingnews.com)
- Insider Selling: Alkermes Plc (ALKS) Director Sells 1,000 Shares of Stock (americanbankingnews.com)
A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, May 30th. BidaskClub upgraded Alkermes from a “sell” rating to a “hold” rating in a research report on Wednesday, May 16th. Credit Suisse Group set a $63.00 target price on Alkermes and gave the company a “buy” rating in a research report on Monday, April 16th. ValuEngine upgraded Alkermes from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 12th. Finally, Bank of America assumed coverage on Alkermes in a research report on Friday, May 11th. They issued a “buy” rating and a $56.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $56.54.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 26th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.40. The firm had revenue of $304.64 million for the quarter, compared to the consensus estimate of $261.58 million. Alkermes had a negative return on equity of 0.29% and a negative net margin of 13.81%. The company’s quarterly revenue was up 39.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.01 EPS. research analysts expect that Alkermes will post -0.71 EPS for the current year.
In related news, Director Floyd E. Bloom sold 20,000 shares of the business’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $43.95, for a total value of $879,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Richard F. Pops sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $44.32, for a total value of $2,216,000.00. Following the completion of the sale, the chief executive officer now owns 716,352 shares in the company, valued at approximately $31,748,720.64. The disclosure for this sale can be found here. Insiders sold a total of 199,842 shares of company stock worth $9,125,380 in the last quarter. Company insiders own 5.34% of the company’s stock.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
See Also: Earnings Per Share (EPS)
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.